Candida Auris Echinocandin Resistance Without FKS Mutations: Ploidy Shifts, CRZ1 Loss of Function and Heteroresistance
The canonical model of echinocandin resistance in Candida auris is target modification: hotspot mutations in FKS1 (and rarely FKS2) raise MICs by orders of magnitude and map cleanly onto treatment failure. A study published in Nature Communications on 15 October 2026 by Gifford, Murphy and colleagues at the University of Exeter and City St George’s, University of London documents the alternative route in clinical detail: two critically ill London patients whose serial bloodstream isolates failed anidulafungin therapy while remaining phenotypically susceptible by standard testing and wild-type at the FKS hotspots. The mechanisms the authors uncover — drug-induced ploidy elevation, heteroresistant sub-populations with small- and large-colony morphotypes, loss-of-function mutations in the calcineurin-responsive transcription factor CRZ1, and compensatory chitin remodelling of the cell wall — amount to an FKS-independent, population-level resistance programme. This guide dissects the evidence, the methodology and the clinical consequences. For the plain-language version, see Candida Auris Explained.
1. Background: Why FKS Wild-Type Failure Is a Problem
Echinocandins inhibit the β-1,3-glucan synthase complex whose catalytic subunit is encoded by FKS1 (with FKS2 partially redundant in some species). Acquired resistance in Candida species is overwhelmingly attributed to amino-acid substitutions in two conserved hotspots of Fks1, which reduce enzyme sensitivity. Clinical microbiology has internalised this model: an isolate that tests susceptible and lacks hotspot mutations is treated as an echinocandin-responsive infection.
The cases reported here break that inference twice over. Both patients’ isolates were classified as anidulafungin-susceptible under the tentative CLSI breakpoint (≥4 μg/mL considered resistant), carried no FKS1/2 hotspot variants, and yet therapy failed — in one case as a breakthrough infection emerging after 33 days of echinocandin treatment. Any diagnostic framework that equates “susceptible MIC, wild-type FKS” with “drug will work” will systematically miss this class of failure.
2. The Clinical Material and Study Design
The investigators worked with serial invasive isolates from the two patients — longitudinal sampling that allows within-host evolution to be observed rather than inferred — together with controlled in-vitro drug-exposure experiments. Whole-genome sequencing against the B8441 reference identified 2,567 SNPs across the isolate set, including 469 non-synonymous variants and 66 coding indels, with the greatest variation clustered in HYR3, encoding a predicted GPI-anchored cell-wall protein, alongside mutations in cell-wall stress-response and trafficking genes. Colony morphotyping under drug pressure resolved two stable phenotypic classes; ploidy was assessed genomically; and the discovery experiment itself was serendipitous — culture plates incubated beyond the standard susceptibility-testing period continued to yield growth over several days.
Methodological strengths: the serial-isolate design ties phenotype to genotype within a single infection; the phenotype (drug survival without FKS mutation) is demonstrated, not merely correlated; and candidate mechanisms are cross-checked between clinical isolates and in-vitro evolution. The limitations are equally clear (Section 7).
3. Finding One: Drug-Induced Ploidy Elevation
Under echinocandin pressure, C. auris cells transiently increased their ploidy, carrying two to four copies of the genome. Elevated ploidy is a recognised accelerant of adaptation: extra chromosome sets buffer deleterious mutations, multiply the mutational target size, and permit recessive loss-of-function alleles to be exposed through subsequent chromosome loss or recombination. Crucially, the increase was transient — a stress-coupled state rather than a fixed genomic rearrangement — which explains both its speed and its invisibility to diagnostics performed on drug-free subculture, where the population reverts.
A nuance worth stating precisely: aneuploidy was not detected in the patients’ isolates as sampled. The ploidy effect was demonstrated under drug exposure in the experimental work, and the clinical isolates displayed the downstream signatures of the programme (heterogeneous sub-populations, CRZ1-mutant fast growers). The honest reading is that ploidy elevation is a demonstrated mechanism of this resistance pathway under drug pressure, with its exact contribution within the two index infections inferred rather than directly observed.
4. Finding Two: Heteroresistance and Colony-Variant Bet-Hedging
The drug-exposed populations resolved into phenotypically heterogeneous sub-populations: small-colony variants (SCVs) growing slowly and displaying drug tolerance, and large-colony variants (LCVs) growing faster with an elevated anidulafungin MIC — frank resistance. This is heteroresistance in its textbook form: a clonal population whose members span the susceptible–resistant range, so that population-averaged assays (a single MIC read from a sweep of growth) report the dominant susceptible phenotype while a resistant minority persists.
Functionally, the SCV/LCV split is bet-hedging. SCVs trade growth for persistence under drug stress; LCVs exploit the drug environment once protective mutations are in place. The clinical correlate is the observed pattern of failure despite susceptible reports — and, in one patient, breakthrough fungaemia after 33 days, the timescale on which a minority variant can expand to dominance under continuous selection.
5. Finding Three: CRZ1 Loss of Function
The genetic signature of the fast-growing LCVs was loss of function in CRZ1: nonsense/stop, deletion and frameshift mutations consistent with Crz1 disruption, present in 82.3% of LCV isolates versus 0% of parental isolates. Crz1 is the downstream transcription factor of the calcineurin pathway and a regulator of cell-wall integrity and stress responses. The result is superficially paradoxical — in C. albicans and C. glabrata, crz1 disruption increases echinocandin susceptibility — but it aligns with recent work showing a C. auris crz1 null mutant is anidulafungin-resistant, and with evidence that Crz1 disruption does not attenuate virulence in a murine model of systemic candidiasis. In C. auris, losing Crz1 appears to rewire wall-stress responses in a way that trades canonical signalling for drug survival — a species-specific rewiring that invalidates cross-species extrapolation of resistance genetics.
6. Finding Four: Chitin Compensation and Wall Remodelling
Echinocandins kill by depleting β-1,3-glucan. Candida species possess a well-documented salvage response: up-regulating chitin synthesis to thicken and stiffen the inner wall layer, mechanically compensating for glucan loss. The C. auris isolates here showed exactly this — increased chitin content and wall thickening across both colony variants — so that drug-treated cells retained wall integrity rather than lysing. In the SCVs, wall remodelling plus slow growth plausibly accounts for tolerance (survival without MIC elevation); in LCVs, the chitin phenotype combines with CRZ1 loss of function and higher MICs. Variation clustering in HYR3 and other wall-protein/trafficking loci suggests the remodelling is genetically entrenched, not purely physiological.
7. The Mechanism at a Glance
| Component | What happens | Consequence | Visible to standard AST? |
|---|---|---|---|
| Ploidy elevation | Cells transiently carry 2–4 genome copies under drug pressure | Mutation supply multiplies; adaptation accelerates | No — reverts on drug-free subculture |
| Heteroresistance | Population splits into susceptible majority + resistant minority | Population-averaged MIC reads “susceptible” | No — requires population analysis profiling |
| SCV / LCV morphotypes | Slow-growing tolerant small colonies; fast-growing resistant large colonies | Bet-hedging: persistence now, expansion later | Partially — only on prolonged incubation |
| CRZ1 loss of function | Nonsense/frameshift/deletion mutations in 82.3% of LCVs vs 0% of parent | Wall-stress signalling rewired; higher anidulafungin MIC | No — outside FKS hotspot panels |
| Chitin compensation | Chitin synthesis up-regulated; inner wall thickens | Mechanical compensation for β-glucan loss; cells do not lyse | No — not assayed clinically |
Detection, accordingly, has to move from single-read assays to population-aware methods: population analysis profiling (plating across a drug-concentration gradient to expose resistant sub-populations), prolonged-incubation susceptibility reads, morphotype-aware colony inspection, and sequencing panels that extend beyond the FKS hotspots to CRZ1 and cell-wall loci. None of these is exotic; all are absent from the default workflow that certified these two infections as drug-susceptible.
8. Limitations
- Two patients, one clade. All isolates belonged to clade I. Whether the ploidy–CRZ1 pathway operates identically in clades II–IV is unknown.
- Mechanistic inference at the clinical step. Ploidy elevation was demonstrated under experimental drug pressure; its presence and timing within the index infections are inferred from population structure.
- Serendipity of discovery. The phenotype emerged on prolonged incubation — a reminder that standard AST incubation windows are themselves a variable; prevalence of this mechanism across isolate collections is unmeasured and could be substantially under-detected.
- Outcome data. The report’s two index patients died (as covered in specialist reporting of the study); with n=2 and critical illness as a confounder, no mortality attribution to the mechanism itself is possible.
9. Clinical and Laboratory Implications
- A susceptible echinocandin MIC does not exclude refractory infection. In a patient with C. auris fungaemia who is not responding, repeat blood cultures and repeat susceptibility testing — ideally including population analysis or prolonged-incubation reads — are the practical safeguards this study supports.
- Breakthrough on therapy is a red flag, not bad luck. New growth after weeks of echinocandin exposure should trigger sequencing that looks beyond FKS hotspots — including CRZ1, wall-protein loci and population heterogeneity.
- Combination therapy has a mechanistic rationale. If resistance is a population programme rather than a single target mutation, simultaneous pressure from two drug classes raises the evolutionary barrier. This is the hypothesis under test in the Exeter-led UKRI Fungi-CARE programme.
- Breakpoint governance. Tentative breakpoints calibrated on FKS-driven resistance may require revisiting as FKS-independent mechanisms are characterised.
10. Conclusion
The study relocates echinocandin resistance in C. auris from a single-gene story to a population-biology story: transient genome multiplication buys evolutionary time, bet-hedging colony variants spread the risk, CRZ1 loss of function and chitin compensation do the biochemical work, and standard diagnostics — averaging across the population — certify the infection as susceptible while it fails therapy. For laboratories and clinicians, the actionable message is procedural humility: in C. auris, a clean test result is a hypothesis about the majority population, not a verdict on the infection.
Sources
- Gifford H, Murphy S, et al. “FKS1/2-variant independent mechanisms underlying the emergence of resistance in echinocandin-refractory Candida auris infections.” Nature Communications, 15 October 2026. doi.org/10.1038/s41467-026-76954-x
- City St George’s, University of London (2026). “Researchers uncover new way deadly fungus Candida auris evades treatment.” citystgeorges.ac.uk
- University of Exeter (2026). “Unexpected discovery of new mechanism which helps deadly fungus Candida auris evade treatment.” news.exeter.ac.uk
This guide is educational information about published research for professional readers. It is not medical advice and does not replace clinical judgement, local antimicrobial policy or specialist microbiology consultation.